InvestorsHub Logo
Followers 0
Posts 79
Boards Moderated 0
Alias Born 06/29/2016

Re: MinnieM post# 2097

Thursday, 07/07/2016 11:49:41 AM

Thursday, July 07, 2016 11:49:41 AM

Post# of 3073
Positive result from this trial could well be a catalyst for the stock. I'm particularly impressed by their designed enrollment of 120 seniors 60-80 years old. This is a group highly likely to benefit from NR/pterostilbene/Basis.

This age group design stands out against:

NR Phase 0 Trial (12 adults age 18-30, AUH/Univ. Copenhagen)
NR Phase 1 Trial (12 adults age 30-55, KGK/ChromaDex)

Of course both were only PK studies. But that, combined with the less favorable age groups, made it inherently less likely to produce exciting result.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDXC News